GRI Bio, Inc. (GRI)
- Previous Close
0.4469 - Open
0.4335 - Bid --
- Ask --
- Day's Range
0.4115 - 0.4501 - 52 Week Range
0.4115 - 62.2300 - Volume
117,672 - Avg. Volume
771,244 - Market Cap (intraday)
1.421M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-27.8000 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
www.gribio.comRecent News: GRI
Performance Overview: GRI
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GRI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GRI
Valuation Measures
Market Cap
1.42M
Enterprise Value
-373.16k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.49
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.03
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-416.93%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.04M
Diluted EPS (ttm)
-27.8000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.81M
Total Debt/Equity (mrq)
5.41%
Levered Free Cash Flow (ttm)
-5.2M